Prothena Corporation plc: Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the